What are the odds of dying from pancreatic cancer?
Evidence quality 4.88/5
Eight-dimension review score against the quality rubric . Each dimension scored 1–5.
- D1 Source grounding
- 5/5
- D2 Source authority
- 5/5
- D3 Arithmetic
- 5/5
- D4 Uncertainty
- 4/5
- D5 Scope
- 5/5
- D6 Prose
- 5/5
- D7 Perception honesty
- 5/5
- D8 Caveat completeness
- 5/5
Lifetime probability · lifetime, global adult
1 in 125
0.8% lifetime chance
range 1 in 200 to 1 in 67
● your factors — click this risk ▾ to reveal
≈ As likely as
Perceived
Pancreatic cancer occupies an unusual position in the public mental model of cancer: most readers do not rank it among the most common killers by raw numbers (correctly — it is not), but most readers do file it as "the bad one", the diagnosis you do not want to hear. That intuition is approximately right. Pancreatic cancer kills fewer people each year than lung, colorectal, liver, stomach, or breast cancer, but it kills a much larger fraction of the people it diagnoses: five-year relative survival sits around 13% in the US and under 12% globally, the worst of any common solid tumor. The fear attached to the word "pancreatic" is a reasonably calibrated response to a genuinely grim case-fatality rate.
Rough estimate: 50% of US adults are very or somewhat worried about getting cancer (Gallup, all sites); pancreatic is widely perceived as the most lethal subtype despite lower incidence
Source: Gallup (2021) — Cancer, Heart Disease Worries Eclipse COVID-19
Actual
~467,000 pancreatic cancer deaths per year globally (~511,000 new cases)
global, all ages, pancreatic cancer only
Show derivation
Starts from the IARC GLOBOCAN 2022 global pancreatic cancer headline: more than 500,000 new cases and almost 470,000 deaths in 2022 worldwide, making pancreatic cancer the 12th most common cancer but the 6th most common cause of cancer death — a ranking mismatch that directly reflects the aggressive case-fatality rate. Spread across a global adult population of ~5.5 billion (age 18+), ~467,000 pancreatic cancer deaths per year is ~0.85 per 10,000 adults per year. Naive 60-year compounding gives ~0.5%; age-weighting (pancreatic cancer mortality is heavily concentrated in the 60-80 band, with hazard several times higher in the last third of adult life than at the population average) pulls the realistic global adult lifetime figure up to roughly 0.8%. The direct US number from ACS is higher: lifetime risk of developing pancreatic cancer is ~1 in 56 for men and ~1 in 60 for women, and with 5-year relative survival of ~13% the implied long-run case-fatality is ~85-90%, giving a US lifetime pancreatic-cancer-death probability of ~1.4% (~1 in 71). Headline figure 0.008 (~1 in 125) with an uncertainty band of 0.005-0.015 to span the global-adult to US-adult range. Scope is global-adult-lifetime to match the cancer-lifetime parent entry; the US row in regional_breakdown anchors the top of the band.
Caveats: Pancreatic cancer is the entry where the case-fatality rate, not the incidence, …
Pancreatic cancer is the entry where the case-fatality rate, not the incidence, is the load-bearing number. Lifetime *incidence* in the US is ~1.6% per SEER — lower than breast, prostate, lung, or colorectal cancer by a wide margin. What makes pancreatic cancer distinctive is the compression between diagnosis and death: ~52,000 US deaths against ~67,000 US diagnoses in the same year gives a deaths-to-cases ratio approaching 0.8, the highest of any common cancer, and 5-year relative survival of 13% is the lowest in the SEER system for a solid tumor. The biology behind that compression is structural: the pancreas sits deep in the retroperitoneum behind the stomach, symptoms are vague and late, and only about 12-15% of tumors are caught at the localized stage where 5-year survival reaches 44%. There is currently no effective population-level screening program for average-risk adults — the USPSTF continues to recommend against routine screening — because the prevalence is too low and the available tests are not specific enough to avoid net harm. Surveillance imaging is only recommended for defined high-risk groups: hereditary pancreatitis, familial pancreatic cancer kindreds, and carriers of certain germline variants. The projected rise to the second leading cause of US cancer death by 2030 reflects improvements in treating the currently-larger cancers more than deteriorating pancreatic outcomes; age-standardized pancreatic cancer mortality has been roughly flat for decades.
Regional breakdown
The headline figure averages across very different populations. Here’s how the probability varies by geography or context:
| Region / context | Lifetime probability | Notes |
|---|---|---|
| Global average | 1 in 125 |
~467,000 pancreatic cancer deaths/yr across ~8B people (IARC GLOBOCAN 2022); age-weighted adult lifetime figure |
| US adult | 1 in 71 |
Derived from ~1.6% SEER lifetime incidence combined with ~85-90% long-run case-fatality; ~1 in 71 |
| Europe | 1 in 67 |
Incidence and mortality rates among the highest worldwide; Central and Eastern European countries sit at the top of the IARC pancreatic cancer ranking |
| Sub-Saharan Africa | 1 in 333 |
Lower incidence; confounded by competing mortality (infectious disease, maternal, injury) removing adults from the denominator before peak pancreatic-cancer-risk age |
Risks at similar odds
Other risks with roughly the same likelihood — useful for calibration.
Recently viewed on this device
Stored locally — clear anytime.
Pick challenger
Pancreatic cancer kills close to 470,000 people a year worldwide per the IARC’s GLOBOCAN 2022 release, against more than 500,000 new cases — the 12th most common cancer globally but the 6th most common cause of cancer death. That ranking mismatch is the whole story. In the US, the American Cancer Society projects roughly 67,500 new pancreatic cancer diagnoses and 52,700 deaths in 2026: a deaths-to-cases ratio near 0.8, higher than any other common cancer. The lifetime risk of developing pancreatic cancer is ~1 in 56 for men and ~1 in 60 for women, and with SEER 5-year relative survival of 13.3% — the lowest of any common solid tumor — the implied US lifetime pancreatic-cancer-death probability is roughly 1 in 71, about 1.4%. Spread across a global adult window, the population figure is lower: roughly 1 in 125 lifetime for a generic adult alive today. Either way, pancreatic cancer kills fewer people each year than lung, colorectal, liver, stomach, or breast cancer — it just kills a much larger fraction of the people it diagnoses.
Why the case-fatality is so high comes down to anatomy and biology more than treatment failure. The pancreas sits deep in the retroperitoneum, symptoms are vague and late, and only about 12-15% of tumors are diagnosed at the localized stage, where 5-year survival reaches 44%. Regional disease drops survival to 17%; distant (metastatic) disease, which is how roughly half of cases present, sits at 3%. There is no effective population-level screening for average-risk adults. The US Preventive Services Task Force continues to recommend against routine screening because the prevalence is too low and the available imaging and blood-based tests are not specific enough to avoid a net harm from false positives and incidental findings. Surveillance imaging is reserved for defined high-risk groups — hereditary pancreatitis kindreds, familial pancreatic cancer kindreds, and carriers of germline BRCA2, Lynch syndrome, PRSS1, CDKN2A, and Peutz-Jeghers variants — where the baseline risk is high enough that the test characteristics land on the right side of the benefit-harm curve.
The trend paragraph is where pancreatic cancer does move around. Rahib and colleagues in Cancer Research projected in 2014 that pancreatic cancer will become the second leading cause of cancer death in the US by 2030, passing breast, prostate, and colorectal to sit behind only lung cancer. The rising relative ranking is not a story about deteriorating pancreatic outcomes — age-standardized pancreatic cancer mortality has been roughly flat for decades — but about improvements in treating the currently-larger cancers and about population ageing pulling more adults into the age window where pancreatic cancer hazard peaks. The short version is that the public intuition filed under “the bad one” is approximately calibrated: the raw count is smaller than the intuition probably suggests, but the conditional probability of dying once diagnosed is worse than any other common cancer, and the gap between those two numbers is the reason the word carries the weight it does.
Claim ledger
Every number below is what each source reported, with the verbatim quote we relied on and how we arrived at our figure. Click any link to verify directly.
-
[1] International Agency for Research on Cancer (IARC) / World Health Organization — Pancreatic Cancer
Pancreatic Cancer- Statistic
More than 500,000 pancreatic cancer cases diagnosed in 2022 and almost 470,000 deaths globally; 12th most common cancer but 6th most common cause of cancer death; one of the cancer types with the least favourable prognosis- Excerpt
“"more than 500 000 people estimated to have been diagnosed with pancreatic cancer in 2022 [...] almost 470 000 deaths in 2022 [...] only the 12th most common cancer type globally [...] the sixth most common cause of cancer death [...] It is one of the cancer types with the least favourable prognosis." ”
- Source data from
- 2024-04-04
- Accessed
- 2026-04-11 · archived copy
- Calculation
- GLOBOCAN 2022 headline used directly as the native number. ~467,000 annual global pancreatic cancer deaths across ~5.5 billion adults is ~0.85 per 10,000 adult-years. Age-weighted over a 60-year adult window — pancreatic cancer hazard in the 60s and 70s is several times the adult average — gives a lifetime adult-lifetime mortality near 0.008 (~1 in 125). The ranking mismatch (12th in incidence, 6th in mortality) is the core quantitative statement of the "diagnosis ≈ death" story and is used directly in the long-form body text.
- Independence
- IARC GLOBOCAN is the upstream dataset used by WHO, ACS international comparisons, and the IHME Global Burden of Disease pancreatic cancer module. Treat this as the canonical global source; the SEER and ACS US numbers below are methodologically independent cross-checks.
-
[2] Surveillance, Epidemiology, and End Results (SEER) Program, National Cancer Institute — Cancer Stat Facts: Pancreatic Cancer
Cancer Stat Facts: Pancreatic Cancer- Statistic
5-year relative survival 13.3% (2015-2021); ~1.6% of men and women will be diagnosed with pancreatic cancer at some point during their lifetime; estimated 67,440 new cases and 51,980 deaths in 2025; 3.3% of all new cancer cases- Excerpt
“"5-Year Relative Survival: 13.3% [...] Approximately 1.6 percent of men and women will be diagnosed with pancreatic cancer at some point during their lifetime [...] Estimated New Cases in 2025: 67,440 [...] Estimated Deaths in 2025: 51,980 [...] 3.3% of all new cancer cases." ”
- Source data from
- 2025-04-01
- Accessed
- 2026-04-11 · archived copy
- Calculation
- SEER gives direct lifetime incidence of ~1.6% for the US population. With 5-year relative survival at 13.3% — the lowest of any common solid tumor — the implied long-run case-fatality is roughly 85-90%. 1.6% lifetime incidence × ~88% long-run case-fatality yields a US lifetime pancreatic-cancer-death probability of ~1.4% (~1 in 71), consistent with the ACS lifetime-risk page. The ratio of annual deaths (~52,000) to annual new cases (~67,000) is ~0.78 on a single-year basis, which understates the long-run case-fatality because most deaths occur outside the diagnosis year. This anchors the US row in the regional breakdown and the top of the Likelier uncertainty band.
- Independence
- SEER (NCI) and IARC GLOBOCAN (WHO) are methodologically independent compilation pipelines. SEER uses US vital registration and population-based cancer registries; IARC aggregates national registry data worldwide.
-
[3] American Cancer Society — Key Statistics for Pancreatic Cancer
Key Statistics for Pancreatic Cancer- Statistic
Lifetime risk of pancreatic cancer ~1 in 56 in men and ~1 in 60 in women; ~67,530 new cases and ~52,740 deaths projected for 2026 in the US; ~3% of US cancers but ~8% of US cancer deaths- Excerpt
“"The average lifetime risk of pancreatic cancer is about 1 in 56 in men and about 1 in 60 in women. [...] About 67,530 people (35,190 men and 32,340 women) will be diagnosed with pancreatic cancer. [...] About 52,740 people (27,230 men and 25,510 women) will die of pancreatic cancer." ”
- Source data from
- 2026-01-16
- Accessed
- 2026-04-11 · archived copy
- Calculation
- ACS projects ~67,530 US new cases and ~52,740 US deaths in 2026 — a ratio of ~0.78 annual deaths to annual diagnoses, which is the single most compressed deaths-to-cases ratio of any common US cancer. The "about 3% of all cancers but about 8% of all cancer deaths" framing is used in the body text as the plain-English version of the GLOBOCAN "12th in incidence, 6th in mortality" ranking. The lifetime-risk-of- developing figures (~1 in 56 men, ~1 in 60 women) combined with the ~85-90% long-run case-fatality from SEER give the ~1.4% US lifetime pancreatic-cancer-death probability used as the US anchor.
- Independence
- ACS Key Statistics and SEER Stat Facts share the same US vital registration and cancer registry upstream. Treat as a single institutional pipeline for the US-specific figures; the IARC source is the methodologically independent global cross-check.
-
[4] American Cancer Society — Survival Rates for Pancreatic Cancer
Survival Rates for Pancreatic Cancer- Statistic
5-year relative survival by stage (SEER 2015-2021): localized 44%, regional 17%, distant 3%, all stages combined 13%- Excerpt
“"Localized 44% [...] Regional 17% [...] Distant 3% [...] All SEER stages combined 13%." ”
- Source data from
- 2025-03-14
- Accessed
- 2026-04-11 · archived copy
- Calculation
- Stage-conditional 5-year survival figures used in the long-form body text. The gap between localized (44%) and distant (3%) is roughly 15x, the largest stage-conditional survival gap of any common cancer in the SEER system. Combined with the fact that only about 12-15% of pancreatic cancers are diagnosed at the localized stage (per SEER staging distribution), the "no effective screening" story falls out arithmetically: the tumor is almost always metastatic or locally advanced at diagnosis.
- Independence
- Draws on the same SEER staging distribution and relative survival pipeline as the SEER Stat Facts source above. Used as the stage- conditional cross-reference, not as an independent verification of the aggregate mortality figure.
-
[5] Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM / Cancer Research — Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States
Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States- Statistic
Pancreas and liver cancers are projected to surpass breast, prostate, and colorectal cancers to become the second and third leading causes of cancer-related death in the US by 2030- Excerpt
“"pancreas and liver cancers are projected to surpass breast, prostate, and colorectal cancers to become the second and third leading causes of cancer-related death by 2030." ”
- Source data from
- 2014-06-01
- Accessed
- 2026-04-11 · archived copy
- Calculation
- Rahib et al. 2014 is the widely cited source for the "second leading cause of US cancer death by 2030" projection used in the body text. The projected rise in ranking is driven almost entirely by improvements in treating the currently-larger cancers (breast, prostate, colorectal) and by population ageing, not by deteriorating pancreatic outcomes — age-standardized pancreatic cancer mortality has been roughly flat for decades. Used as the "trend" paragraph anchor, not as part of the headline probability calculation.
- Independence
- Rahib et al. projects from SEER incidence and NCHS mortality data, so upstream is the same as the SEER/ACS sources. Independent analytically in the sense that it is a projection model rather than a retrospective count, but not an independent data pipeline.